Skip to content

Effect of DHEA on Patients With Poor Ovarian Responds

Effect of Dehydroepiandrosterone on Live Birth Rate in Subfertile Patients With Poor Ovarian Responds

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02432248
Enrollment
350
Registered
2015-05-04
Start date
2015-02-28
Completion date
2024-12-31
Last updated
2023-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subfertility

Keywords

DHEA, live birth rate, poor ovarian responder

Brief summary

The purpose of this study is to investigate the effect of DHEA for treatment of subfertile patients with poor ovarian reserve and post-treatment evaluation of IVF outcome.

Detailed description

The aim of this randomized controlled study is to compare the effect of DHEA and placebo on live birth rate in poor ovarian responders. Consecutive infertile women attending the subfertility clinic for IVF treatment will be approached. Those fulfilling the selection criteria would be recruited and a written consent will be obtained after detailed explanation and counseling. Baseline assessment will be performed at early follicular phase (Day 2 or 3) at recruitment. Patient characteristics including age, body mass index (BMI), and smoking status would be recorded and blood test including follicular stimulating hormone (FSH), estradiol (E2), testosterone and anti-Müllerian hormone (AMH) would be checked. Pelvic scan will be performed to assess the total antral follicle count (AFC) and total ovarian volume. Subjects will be randomized divided into two groups: 1. DHEA group: Subjects will take DHEA (Vitacost) 25mg three times a day for 12 weeks prior to the start of IVF treatment. 2. Placebo group: Subjects will take placebo three times a day for 12 weeks prior to the start of IVF treatment. Ultrasound assessment will be repeated in follicular phase (D2 or 3) of every month or cycle followed by a IVF treatment using antagonist protocol based on our standard departmental regimen. Cycle characteristics including the dose of gonadotrophins use, duration of stimulation, number of oocytes obtained, number of fertilized embryos and good quality embryos will be recorded and follicular fluid will be saved for hormonal profiles.

Interventions

DRUGDehydroepiandrosterone

75mg/day, PO for 90 days

OTHERplacebo(medical starch)

75mg/day, PO for 90 days

Sponsors

First Affiliated Hospital, Sun Yat-Sen University
CollaboratorOTHER
Renmin Hospital of Wuhan University
CollaboratorOTHER
The Affiliated Hospital of Inner Mongolia Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 42 Years
Healthy volunteers
No

Inclusion criteria

* Indicated for IVF treatment according to our standard department protocol * Age \< 42 * Regular menstrual cycles (21-35 days) Poor ovarian responders are defined according to the Bologna criteria fulfilling 2 out of 3 of the following: * Advanced maternal age (≥40) or any other genetic or acquired risk factor for POR * Previous poor ovarian response (POR) (≤3 oocytes with a conventional stimulation protocol using at least 150IU gonadotrophins per day) * Abnormal ovarian reserve test (i.e. AFC \< 5-7 or AMH \< 0.5-1.1ng/ml). Alternatively, two episodes of POR after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ORT.

Exclusion criteria

* Previous chemotherapy or pelvic irradiation * Polycystic ovarian syndrome or polycystic ovaries * On hormonal supplementation for any indication at the time of recruitment (e.g. estrogen, testosterone or DHEA)

Design outcomes

Primary

MeasureTime frameDescription
Live birth rateParticipants will be followed for live birth rate up to 1 year.Compare the live birth rate between DHEA group and placebo group

Secondary

MeasureTime frameDescription
Pregnancy rateParticipants will be followed for pregnancy rate up to 1 year.Compare the pregnancy rate between DHEA group and placebo group

Countries

China

Contacts

Primary ContactYu Wang, PHD
wuai1544@163.com86-18604718958

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026